Sulfasalazine | Sulfasalazine-EN tablets 500 mg, 50 pcs.
Special Price
$19.40
Regular Price
$27.00
In stock
SKU
BID464780
Release form
Coated tablets.
Coated tablets.
Release form
Coated tablets.
Packing
50 pcs.
Pharmacological action
Sulfasalazin-EN - antimicrobial and anti-inflammatory intestinal agent.
Sulfasalazine selectively accumulates in the connective tissue of the intestine with the release of 5-aminosalicylic acid (5-ASA), possessing anti-inflammatory activity, and sulfapyridine, which has antimicrobial bacteriostatic activity against diplococci, streptococci, gonococci, E. coli.
Pharmacokinetics
About 30% of sulfasalazine in enteric coated tablets are absorbed from the small intestine, the remaining 70% are digested with intestinal microflora to form 60-80% sulfapyridine and 25% 5-ASA. Sulfasalazine reaches its maximum concentration 3-12 hours after taking enteric-coated tablets. Communication with plasma proteins of sulfasalazine - 99%, sulfapyridine - 50%, 5-ASA - 43%. Sulfapyridine is metabolized in the liver by hydroxylation to form inactive metabolites, 5-ASA by acetylation. The half-life of sulfasalazine is 5-10 hours, sulfapyridine - 6-14 hours, 5-ASA - 0.6-1.4 hours. It is excreted through the intestines - 5% sulfapyridine and 67% 5-ASA, kidneys - 75-91% of absorbed sulfasalazine (within 3 days).
Indications
ulcerative colitis (treatment of exacerbations and maintenance therapy in remission)
Crohn’s disease (mild to moderate forms in the exacerbation phase)
rheumatoid arthritis
juvenile rheumatoid arthritis.
Contraindications
blood disease
porphyria
severe hepatic impairment
severe renal impairment
enzyme deficiency glucose-6-phosphate dehydrogenase
children under 5 years of age
hypersensitivity to sulfamic acid.
Composition
1 enteric-coated tablet contains: active ingredient: sulfasalazine coated with povidone (corresponding to 500 mg) sulfasalase 535,000 mg
excipients: pregelatinized starch, magnesium stearate, colloidal silicon dioxide, anhydrous.
Dosage and Administration
Inside. Adults on the first day of treatment are prescribed a dose of 500 mg 4 times / day. on the 2nd day - 1 g 4 times / day. on the 3rd and subsequent days - 1.5-2 g 4 times / day. After the acute clinical symptoms of ulcerative colitis subside, sulfasalazin-EN is prescribed in a maintenance dose of 500 mg 3-4 times / day. for several months.
Children aged 5-7 years are prescribed 250-500 mg 3-6 times / day. Children over 7 years old are prescribed 500 mg 3-6 times / day. Sulfasalazine-EN should be taken after meals.
Side effects of
From the central nervous system and peripheral nervous system: headache, dizziness, tinnitus, ataxia, cramps, sleep disturbances, hallucinations, peripheral neuropathy.
From the urinary system: impaired renal function, interstitial nephritis.
From the digestive system: nausea, vomiting, diarrhea, abdominal pain, anorexia, hepatitis, pancreatitis.
From the respiratory system: interstitial pneumonitis and other lung tissue lesions.
From the hemopoietic system: anemia, leukopenia, thrombocytopenia, agranulocytosis.
From the reproductive system: transient oligospermia, infertility.
Allergic reactions: skin rash, fever, anaphylactic shock.
Others: staining of the skin, urine, soft contact lenses yellow is possible.
Storage conditions
In the dark place at a temperature of no higher than 25 РC.
Expiration
2 years.
Deystvuyuschee substances
Sulfasalazine
Terms and conditions
prescription
dosage form
tablets
KRKA d.d. Novo mesto AO, Slovenia
Coated tablets.
Packing
50 pcs.
Pharmacological action
Sulfasalazin-EN - antimicrobial and anti-inflammatory intestinal agent.
Sulfasalazine selectively accumulates in the connective tissue of the intestine with the release of 5-aminosalicylic acid (5-ASA), possessing anti-inflammatory activity, and sulfapyridine, which has antimicrobial bacteriostatic activity against diplococci, streptococci, gonococci, E. coli.
Pharmacokinetics
About 30% of sulfasalazine in enteric coated tablets are absorbed from the small intestine, the remaining 70% are digested with intestinal microflora to form 60-80% sulfapyridine and 25% 5-ASA. Sulfasalazine reaches its maximum concentration 3-12 hours after taking enteric-coated tablets. Communication with plasma proteins of sulfasalazine - 99%, sulfapyridine - 50%, 5-ASA - 43%. Sulfapyridine is metabolized in the liver by hydroxylation to form inactive metabolites, 5-ASA by acetylation. The half-life of sulfasalazine is 5-10 hours, sulfapyridine - 6-14 hours, 5-ASA - 0.6-1.4 hours. It is excreted through the intestines - 5% sulfapyridine and 67% 5-ASA, kidneys - 75-91% of absorbed sulfasalazine (within 3 days).
Indications
ulcerative colitis (treatment of exacerbations and maintenance therapy in remission)
Crohn’s disease (mild to moderate forms in the exacerbation phase)
rheumatoid arthritis
juvenile rheumatoid arthritis.
Contraindications
blood disease
porphyria
severe hepatic impairment
severe renal impairment
enzyme deficiency glucose-6-phosphate dehydrogenase
children under 5 years of age
hypersensitivity to sulfamic acid.
Composition
1 enteric-coated tablet contains: active ingredient: sulfasalazine coated with povidone (corresponding to 500 mg) sulfasalase 535,000 mg
excipients: pregelatinized starch, magnesium stearate, colloidal silicon dioxide, anhydrous.
Dosage and Administration
Inside. Adults on the first day of treatment are prescribed a dose of 500 mg 4 times / day. on the 2nd day - 1 g 4 times / day. on the 3rd and subsequent days - 1.5-2 g 4 times / day. After the acute clinical symptoms of ulcerative colitis subside, sulfasalazin-EN is prescribed in a maintenance dose of 500 mg 3-4 times / day. for several months.
Children aged 5-7 years are prescribed 250-500 mg 3-6 times / day. Children over 7 years old are prescribed 500 mg 3-6 times / day. Sulfasalazine-EN should be taken after meals.
Side effects of
From the central nervous system and peripheral nervous system: headache, dizziness, tinnitus, ataxia, cramps, sleep disturbances, hallucinations, peripheral neuropathy.
From the urinary system: impaired renal function, interstitial nephritis.
From the digestive system: nausea, vomiting, diarrhea, abdominal pain, anorexia, hepatitis, pancreatitis.
From the respiratory system: interstitial pneumonitis and other lung tissue lesions.
From the hemopoietic system: anemia, leukopenia, thrombocytopenia, agranulocytosis.
From the reproductive system: transient oligospermia, infertility.
Allergic reactions: skin rash, fever, anaphylactic shock.
Others: staining of the skin, urine, soft contact lenses yellow is possible.
Storage conditions
In the dark place at a temperature of no higher than 25 РC.
Expiration
2 years.
Deystvuyuschee substances
Sulfasalazine
Terms and conditions
prescription
dosage form
tablets
KRKA d.d. Novo mesto AO, Slovenia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review